Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15420MR)

This product GTTS-WQ15420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15420MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6953MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5462MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ381MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ14422MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ5793MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ473MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9437MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ13101MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW